Related Experiment Videos
Bumetanide and furosemide
Clinical Pharmacology and Therapeutics
|August 1, 1983
Summary
Bumetanide shows 200% higher bioavailability and significantly greater potency than furosemide, with both drugs rapidly absorbed and excreted unchanged in urine. This study compares their pharmacokinetic and pharmacodynamic properties in healthy subjects.
Area of Science:
- Pharmacology
- Nephrology
- Clinical Therapeutics
Background:
- Furosemide and bumetanide are loop diuretics used to treat fluid overload.
- Understanding their comparative pharmacokinetic and pharmacodynamic profiles is crucial for optimizing patient care.
Purpose of the Study:
- To compare the response to and handling of furosemide and bumetanide in normal subjects.
- To determine the bioavailability, excretion, and dose-response relationships of both diuretics.
Main Methods:
- Administered oral doses of furosemide (20-80 mg) and bumetanide (0.5-2 mg).
- Administered intravenous doses of bumetanide (0.5-1 mg).
- Measured urinary excretion of unchanged drugs and sodium to assess pharmacokinetics and pharmacodynamics.
Main Results:
- Both drugs were rapidly absorbed, with peak urinary excretion at a median of 75 minutes.
- Approximately 30% of oral doses were excreted unchanged, with no dose-dependent elimination.
- Bumetanide exhibited 80% bioavailability, compared to approximately 40% for furosemide.
- Bumetanide demonstrated significantly greater potency, with a lower dose inducing half-maximal sodium excretion response.
Conclusions:
- Bumetanide possesses substantially higher bioavailability and greater potency than furosemide.
- These differences in pharmacokinetic and pharmacodynamic properties distinguish bumetanide from furosemide, potentially influencing their clinical applications.